• Kimball Electronics discussed third-quarter fiscal 2026 results on May 6 with CEO Richard Phillips, CFO Jana Croom, VP of Investor Relations and Strategic Development and Treasurer Andy Regrut; Q&A included analysts from B. Riley, Cantor Fitzgerald, Lake Street, Sidoti.
• Net sales $352.9 million; Medical sales $106 million rose 10% sequentially, with management citing 17% year-over-year growth in Medical on a normalized basis due to prior-year $24 million consigned-inventory sale.
• Guidance reaffirmed for revenue $1.4 billion-$1.46 billion; adjusted operating margin expected at high end of 4.2%-4.5%, implying Q4 sales $370 million-$380 million with adjusted operating margin 4.4%-4.6%.
• Indianapolis 300,000-square-foot medical manufacturing facility expected to begin production by end of calendar year; CFO flagged 40-50 basis points gross-margin headwind in fiscal 2027 from overlapping facility costs, with pressure easing in fiscal 2028 as volumes ramp.
• Management highlighted active M&A work to accelerate Medical CMO strategy, targeting tuck-ins that add capabilities or geographies; balance sheet described as positioned to act, with $358.5 million liquidity at quarter end.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kimball Electronics Inc. published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.